-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BoswKnYk1NJZCEU8MBpNP52HMRVG1kj+39MziiR4k6ZXjEXpP60rjpdpR9r4fGde 3IJwg5QfiC+h3IUux+OYaw== 0001477126-10-000004.txt : 20101110 0001477126-10-000004.hdr.sgml : 20101110 20101110171946 ACCESSION NUMBER: 0001477126-10-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101108 FILED AS OF DATE: 20101110 DATE AS OF CHANGE: 20101110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Durham Mark Andrew CENTRAL INDEX KEY: 0001477126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14956 FILM NUMBER: 101181031 MAIL ADDRESS: STREET 1: 75 PROSPECT STREET CITY: MADISON STATE: NJ ZIP: 07940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc. CENTRAL INDEX KEY: 0000885590 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 BUSINESS PHONE: 905 286-3000 MAIL ADDRESS: STREET 1: 7150 MISSISSAUGA ROAD STREET 2: MISSISSAUGA CITY: ONTARIO STATE: A6 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL Corp DATE OF NAME CHANGE: 20100416 FORMER COMPANY: FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL DATE OF NAME CHANGE: 19960522 4 1 primary_doc.xml PRIMARY DOCUMENT X0303 4 2010-11-08 0 0000885590 Valeant Pharmaceuticals International, Inc. VRX 0001477126 Durham Mark Andrew 7150 MISSISSAUGA ROAD MISSISSAUGA A6 L5N 8M5 ONTARIO, CANADA 0 1 0 0 SVP, Human Resources Common Shares, no par value 2010-11-08 4 M 0 102658 0 A 103908 D Common Shares, no par value 2010-11-08 4 F 0 46628 26.12 D 57280 D Restricted Share Units 2010-11-08 4 M 0 51329 D 2010-11-08 2010-08-05 Common Shares, no par value 51329 0 D Each Restricted Share Unit ("RSU") represents a contingent right to receive one common share, no par value, of Valeant Pharmaceuticals International, Inc. and is subject to performance based vesting criteria, providing for vesting ranging from zero (0) to two hundred percent (200%). Represents performance based RSUs that accelerated at 200% in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010. Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of RSUs. By:Angie Palmer For: Mark Durham 2010-11-10 -----END PRIVACY-ENHANCED MESSAGE-----